T-Cell Therapy Against Patient-Specific Cancer Mutations
Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and therefore, may serve as therapeutic targets.
Scientists at the National Cancer Institute's Surgery Branch developed a method to identify T cells that specifically recognize immunogenic mutations expressed only by cancer cells. The scientists identified cancer-specific mutations from a patient with widely metastatic cholangiocarcinoma by sequencing tumor samples and comparing with normal cells. Using tandem minigene constructs encoding all of the mutations expressed by a patient's tumor, the inventors identified T cells that recognized the immunogenic mutations from the same patient. These mutation-reactive T cells have the potential to eliminate the cancer cells while sparing normal tissues since normal tissues do not express the mutations. The mutation-reactive T cells were expanded in vitro, and then infused as a highly pure population back into the same patient. The patient experienced tumor regression when treated with this approach.
Potential Commercial Applications: | Competitive Advantages: |
|
|
Development Stage:
Clinical
Inventors:
Eric Tran (NCI) ➽ more inventions...
Yong-Chen Lu (NCI) ➽ more inventions...
Paul Robbins (NCI) ➽ more inventions...
Steven Rosenberg (NCI) ➽ more inventions...
Intellectual Property:
U.S. Pat: 6686008 issued 2020-04-03
Publications:
Tran E, et al. PMID 24812403
Robbins P, et al. PMID 23644516
Tran E, et al. PMID 25046408
Collaboration Opportunity:
Licensing and research collaboration
Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515
OTT Reference No: E-233-2014
Updated: Oct 19, 2020